CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Sofosbuvir/ velpatasvir

Last Updated: March 23, 2016
Result type: Reports
Project Number: SR0486-000
Product Line: Reimbursement Review

Generic Name: Sofosbuvir/ velpatasvir

Brand Name: Epclusa

Manufacturer: Gilead Sciences Canada, Inc.

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 26, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions